News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Enrollment Continues Into Bio-Path Holdings, Inc. (BPTH) Phase I Clinical Trial


6/19/2014 10:01:28 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HOUSTON--(BUSINESS WIRE)--Bio-Path Holdings, Inc., (NASDAQ:BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced enrollment is now resuming into its Phase I clinical trial evaluating its lead compound, Liposomal Grb-2, in blood cancers. Sufficient drug quantities are now in place to complete Cohort 6 of the trial.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES